Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
- サイト内被引用 Cited by
要旨●I型胃カルチノイド症例の長期予後について多施設後ろ向き検討を行った.腫瘍はすべて胃体部・胃穹窿部に存在し,腫瘍径は10mm以下が多く,ほとんどが粘膜・粘膜下層に限局していた.腫瘍径21mm以上では脈管侵襲の割合が高い傾向であった.治療については,近年になって,外科的切除が減少し,内視鏡的切除,特にESDによる切除の割合が増加していた.また欧米の報告と比べると,自己免疫性疾患としての特徴に乏しく,H. pylori感染など,発生に関与する他因子の存在が示唆された.一方,脈管侵襲・リンパ節転移はあっても肝転移など遠隔転移は存在せず,長期予後〔観察期間中央値7(0〜20)年〕についても,無病生存率97.6%(80/82),疾患特異的生存率は100%(82/82)と大変良好で,欧米の報告も同様であった.
This study evaluated different treatment approaches and clinical outcomes in patients with TIGCs(Type I gastric carcinoids)in Japan. Between 1991 and 2011, 82 patients with TIGCs were identified at multi-center institutions in Japan. All tumors were in the gastric corpus or fornix, and a large proportion of tumors were less than 10 mm in diameter. Most of the cases were histologically confirmed as mucosal or submucosal tumors. In recent years, the ratio of surgical resection for TIGC has decreased, while the proportion of endoscopic resection for TIGC, particularly ESD, has increased. In addition, TIGC in Japan is not associated with autoimmune diseases as seen in European and American reports ; therefore, it was suggested that other underlying factors such as Helicobacter pylori infection may exist. None of the patients showed rapidly growing tumors or metastasis. The median(range)follow-up period was 7 years(0-20 years). Recurrence-free survival was 97.6% and disease-specific survival was 100% in all patients.
Copyright © 2017, Igaku-Shoin Ltd. All rights reserved.